European Journal of Nuclear Medicine and Molecular Imaging

, Volume 37, Issue 8, pp 1575–1593

Radiopharmaceuticals for positron emission tomography investigations of Alzheimer’s disease

Authors

    • Department of Nuclear Medicine, PET and Cyclotron UnitOdense University Hospital
  • Christer Halldin
    • Karolinska Institutet, Department of Clinical Neuroscience, Psychiatry SectionKarolinska University Hospital Solna
  • Juha O. Rinne
    • Turku PET Centre
Review Article

DOI: 10.1007/s00259-009-1301-z

Cite this article as:
Någren, K., Halldin, C. & Rinne, J.O. Eur J Nucl Med Mol Imaging (2010) 37: 1575. doi:10.1007/s00259-009-1301-z

Abstract

Alzheimer’s disease (AD) is a common degenerative neurological disease that is an increasing medical, economical, and social problem. There is evidence that a long “asymptomatic” phase of the disease exists where functional changes in the brain are present, but structural imaging for instance with magnetic resonance imaging remains normal. Positron emission tomography (PET) is one of the tools by which it is possible to explore changes in cerebral blood flow and metabolism and the functioning of different neurotransmitter systems. More recently, investigation of protein aggregations such as amyloid deposits or neurofibrillary tangles containing tau-protein has become possible. The purpose of this paper is to review the current knowledge on various 18F- and 11C-labelled PET tracers that could be used to study the pathophysiology of AD, to be used in the early or differential diagnosis or to be used in development of treatment and in monitoring of treatment effects.

Keywords

ADAlzheimer’s diseaseCognitionPositron emission tomographyPET11C18F

Copyright information

© Springer-Verlag 2009